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Unveiling some FDA-approved 
drugs as inhibitors of the store-
operated Ca2+ entry pathway
Saifur Rahman & Taufiq Rahman
The store-operated calcium entry (SOCE) pathway is an important route for generating cytosolic 
Ca2+ signals that regulate a diverse array of biological processes. Abnormal SOCE seem to underlie 
several diseases that notably include allergy, inflammation and cancer. Therefore, any modulator 
of this pathway is likely to have significant impact in cell biology under both normal and abnormal 
conditions. In this study, we screened the FDA-approved drug library for agents that share significant 
similarity in 3D shape and surface electrostatics with few, hitherto best known inhibitors of SOCE. 
This has led to the identification of five drugs that showed dose-dependent inhibition of SOCE in cell-
based assay, probably through interacting with the Orai1 protein which effectively mediates SOCE. 
Of these drugs, leflunomide and teriflunomide could suppress SOCE significantly at clinically-relevant 
doses and this provides for an additional mechanism towards the therapeutic utility of these drugs as 
immunosuppressants. The other three drugs namely lansoprazole, tolvaptan and roflumilast, were 
less potent in suppressing SOCE but were more selective and thus they may serve as novel scaffolds for 
future development of new, more efficacious SOCE inhibitors.
Ca2+ is a universal and versatile intracellular messenger which regulates almost every aspect of cellular life ranging 
from fertilisation to cell death. Generation of Ca2+ signals involves a transient increase in the cytosolic free Ca2+ 
concentration from the resting low (≤500 nM) level up to ~1 μM1. To do this, cells rely on stimulus-dependent 
release of Ca2+ from the internal stores (e.g. the endoplasmic reticulum, ER) as well as on Ca2+ entry from the 
extracellular space through various plasma membrane (PM)-localised, Ca2+ permeable ion channels that can be 
either ligand- or voltage-gated. However, for many cells a major source of cytosolic Ca2+ signals happens to be a 
distinct and unique Ca2+ entry mechanism namely the store-operated Ca2+ entry (SOCE). SOCE occurs when 
intracellular Ca2+ stores are rapidly depleted, which then triggers a more sustained Ca2+ entry via PM-localised 
Orai1 channels (also known as Ca2+ release-activated Ca2+ channels, CRAC channels). The latter are activated 
upon binding with the stromal interaction molecule-1 (STIM1) proteins which are expressed within the ER mem-
brane and effectively ‘sense’ the Ca2+ drop within the ER lumen. Although SOCE was first identified in mast cells 
and mostly studied in this and other non-excitable cells, evidence amass that such Ca2+ entry pathway probably 
exists in all kind of cells including even the excitable ones2.
SOCE is traditionally well known to serve as the major route for replenishing the depleted intracellular Ca2+ 
stores. Apart from such important housekeeping task, evidence continues to emerge that SOCE can also deliver 
spatio-temporally complex Ca2+ signals for regulating some more specific biological processes such as exocyto-
sis, mitochondrial metabolism, gene expression, cell growth and proliferation3. In recent years, aberrant Orai1 
channel activity has been noted in several human diseases, including severe combined immunodeficiency disor-
ders, allergy, thrombosis, acute pancreatitis, inflammatory bowel disease, rheumatoid arthritis and cancer4. Thus 
there have been legitimate active interests in the academia and industries for developing specific inhibitors of 
SOCE/CRAC channels. Although a number of small molecules have emerged as SOCE inhibitors by now3–6, most 
of them by far have not reached clinical trials, primarily owing to their inadequate selectivity and high toxicity. It 
is however encouraging to note that a member of the CalciMedica (CM4620) series has recently reached Phase I 
clinical trials with intended use for treating acute pancreatitis7. Nevertheless, the need for identifying new scaf-
folds against SOCE/CRAC channels remains still valid for future development of more specific inhibitors with 
improved potency, greater selectivity and known mechanism of action.
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Given the crucial involvement of the SOCE-derived Ca2+ signals in the regulation of some specific cellular 
processes mentioned above, any modulator of this pathway is likely to have substantial effects on cell biology 
under normal as well as pathological conditions. Thus, there can be drug molecules possessing hitherto undis-
closed capacity for modulating SOCE at therapeutically relevant doses. Such property could potentially contribute 
to their clinical benefits within a polypharmacological context or could perhaps explain some of their side effects. 
In the present study, we aimed at identifying any such drug(s) using a ligand-based in silico approach. For this, we 
have exploited the structures of few best known SOCE inhibitors as baits and virtually screened FDA-approved 
drug library to find drugs that share significant similarities in 3D shape and electrostatics with these baits and 
thus are likely to phenocopy them. Indeed through subsequent bioassay of the shortlisted drug hits, we identified 
five drugs that dose-dependently suppress SOCE and these drugs do not have any previous report of such action. 
For two of the five drugs, significant inhibition of SOCE seems to occur at a clinically relevant dose and thus this 
could contribute to their therapeutic utility for indicated conditions. The other three drugs can serve as novel 
scaffold for future development of novel series of SOCE inhibitors. Our finding thus re-validates the utility of such 
computational approach in drug repurposing endeavour as indicated before8,9.
Results
Ligand-based virtual screening and identification of hits for bioassay. We first sought out to eval-
uate the performance of our in silico protocol and for this, we screened conformer libraries generated from the 
TOCRIS™ (http://zinc15.docking.org/catalogs/tocris/) and the MedchemExpress™ (http://zinc15.docking.org/
catalogs/mce/) libraries using BTP2 and Pyr6 as baits, respectively. We chose these libraries as BTP2 and Pyr6 are 
enlisted as purchasable items in TOCRIS and the MedChemExpress databases, respectively. It was reassuring to 
note that BTP2 and Pyr6 ranked the top in both ROCS based primary screening as well as in EON based re-rank-
ing of ROCS outputs from screening of TOCRIS and MedChemExpress libraries, respectively (Supplementary 
Tables 1 and 2). We therefore went ahead with our protocol to screen a conformer library generated from the 
eDrugs3D database10 that contains all FDA-approved drugs. As baits, we used Synta66 and AnCoA4, in addition 
to BTP2 and Pyr6 (Supplementary Fig. 1). After visual inspection of each hit for electrostatic similarity and con-
sidering their ranks in ROCS and EON based outputs, availability and any previous record of having any effect 
on cellular calcium signals, we purchased total 11 drugs (Supplementary Table 3). Of these, we could not screen 
flutamide as it was coloured and incompatible with our calcium indicator. So the final list of 10 drugs that were 
tested in single cell Ca2+ imaging include leflunomide, teriflunomide, tolvaptan, conivaptan, omeprazole, lanso-
prazole, rufinamide, prazosin, terazosin and roflumilast.
Evaluation of the effects of chosen drugs on the store-operated calcium entry (SOCE). To eval-
uate the effect of the purchased drugs on SOCE, we used Fura-2 based Ca2+ imaging11,12 primarily with RBL-1 
cells which are widely-used for studying SOCE. These cells were first treated, in absence of extracellular Ca2+, 
with thapsigargin (Tg) that passively depletes the intracellular Ca2+ store by inhibiting the serco-endoplasmic 
Ca2+-ATPase (SERCA). SOCE was evident in these cells soon after the addition of 2 mM Ca2+ to the extracellular 
(bath) solution. We first screened the drugs at 100 μM and at this concentration most of the purchased drugs 
showed substantial (by ≥60%) suppression of SOCE. Only prazosin, terazosin and rufinamide had no effect on 
SOCE at this high concentration and therefore discarded for further investigation (Fig. 1a,b).
In order to identify the more potent drugs from the list, we then screened all the remaining drugs at 
10-fold lower concentration (10 μM) and apart from omeprazole and conivaptan, all drugs retained their abil-
ity to inhibit SOCE significantly at this concentration (Fig. 1c). For those 5 drugs which significantly sup-
pressed SOCE at 10 μM, we carried out complete concentration-response studies with a view to evaluating 
the concentration-dependence of their action as well as determining the half-maximal inhibitory concen-
tration (IC50) for each drug. As can be seen in Fig. 2, all 5 drugs as well as the positive control, BTP2 showed 
dose-dependent suppression of SOCE over the concentration range of 300 μM to 10 μM. At concentration 
below 10 μM, none of the drugs under the standard experimental protocol (~20 min pre-incubation before 
the Ca2+ add back) manifested any significant SOCE-inhibitory property. Since the maximum concentration 
of the drugs used in the study (i.e. 300 μM) was fairly high, we also assessed the possible toxic effects of these 
drugs at such high concentration using a widely-used, propidium iodide-based cell viability assay13. It was 
reassuring that none of drugs even at their highest concentration used in our calcium imaging, was toxic to 
RBL-1H cells (Supplementary Fig. 2).
To support our findings from the Ca2+ imaging experiments, we also carried out whole-cell recording of 
SOCE-representative current (ICRAC) from RBL-1H cells on a limited scale, following ~20 min pretreatment with 
the chosen drugs (20 μM) or BTP2 (10 μM). As shown in Fig. 3, teriflunomide and tolvaptan as well as BTP2 
showed substantial and significant inhibition of the ICRAC. Other drugs showed similar trend but the results were 
not included due to inadequate number of experimental repeats.
In some previous studies, pyrazole type inhibitors of SOCE such as BTP2 was found to inhibit SOCE more 
substantially following much longer (1 hr to 24 hr) pre-treatment14,15. All of our above mentioned drugs share 
reasonably good similarity in 3D shape and electrostatics with pyrazole type inhibitors such as BTP2 and Pyr6 
(Supplementary Table 3, Supplementary Figs 3–6). We therefore sought to evaluate whether longer incubation 
of the cells with these drugs could improve their potency for SOCE suppression. For this, RBL-1H cells were 
pre-treated with 1 μM of the selected drugs and SOCE was recorded after 48 hours. As can be seen in Fig. 4, 
significantly inhibition of SOCE was observed only for cells treated with leflunomide, teriflunomide and BTP2.
In order to know whether the observed effect of the five drugs on SOCE was cell-type specific or not, we 
screened those 5 drugs at 10 μM dose against SOCE also in SHSY-5Y cells (a human neuroblastoma cell line) 
using the same protocol we used for the RBL-1 cells. As can be seen in Supplementary Fig. 7, all those drugs 
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retained their ability to suppress SOCE significantly in SHSY-5Y cells as well, indicating that the observed effect 
was largely cell-type independent. It was interesting to note that the extent of SOCE suppression by all these drugs 
excluding roflumilast was seemingly higher for SHSY-5Y cells than in RBL-1 cells.
Hitherto we used our drugs in a ‘semi-acute’ manner i.e. we exposed the cells to the drugs ~20 min prior to the 
Ca2+ add back during the Ca2+ imaging experiments. Next we went on to evaluate whether the drugs could affect 
SOCE if added in a more acute way. With this aim, we applied the drugs at 50 μM concentration in a realistically 
acute manner i.e. ~10 s prior to adding Ca2+ to the extracellular media. It turned out that 3 drugs namely lefluno-
mide, teriflunomide and tolvaptan, could significantly suppress SOCE when added in this acute fashion (Fig. 5). 
The known SOCE inhibitor - BTP2 as well as the other two drugs - roflumilast and lansoprazole were without any 
effect under such experimental condition.
Next, we investigated whether the drugs that suppressed SOCE in our experiments, could affect Ca2+ entry in 
RBL-1H cells in response addition of 1-oleoyl-2-acetyl-sn-glycerol (OAG). The latter is a membrane permeable, 
synthetic analog of DAG and is well known to activate members of the TRPC family of ion channels including 
TRPC3, TRPC6 and TRPC716. As can been seen in Fig. 6, addition of OAG triggered Ca2+ signals that were evi-
dent only in presence of extracellular Ca2+ in these cells, indicating that it was Ca2+ entry. Among the tested drugs 
at 10 μM dose, only leflunomide and teriflunomide showed significant inhibition of the OAG-evoked Ca2+ and 
thus these drugs are likely to have inhibitory effect on the activity of TRPC family members.
Evaluation of the effects of chosen drugs on the nuclear translocation of NFAT. To determine 
whether the chosen drugs could affect SOCE-dependent cell signalling and relevant biological responses in intact 
cells, we evaluated their effect on the nuclear translocation of the nuclear factor of activated T cells (NFAT). 
The latter is a transcription factor which is well known in lymphocytes and relevant cells to require specifi-
cally the SOCE-derived Ca2+ signals for its activation17. For this, we used HeLa cells stably expressing NFAT1 
(1-460)-GFP18. As can be observed in Fig. 7, ionomycin treatment (1 μM for 40 min) significantly increased the 
Figure 1. Evaluation of the effects of chosen drugs on the store-operated calcium entry (SOCE) in RBL-1 cells 
triggered by thapsigargin using Fura-2 based Ca2+ imaging experiments. (a) Sample traces representing Ca2+ 
signals (indicated by Fura-2 fluorescence ratio) triggered by adding 2 μM of thapsigargin (Tg) to RBL-1 cells 
with or without pre-treatment of the chosen drugs (shown in various coloured lines, each at 100 μM dose). (b) 
Histograms showing the peak SOCE levels triggered by Tg in control cells and cells treated with 100 μM of each 
drug. (c) Histograms showing the peak SOCE levels triggered by Tg in control cells and cells pre-treated with 
each drug at 10 μM dose. Each value (mean ± SEM) was derived from 3–5 individual experiments and a total 
of 30–80 cells. The statistical comparison among the values for all conditions was determined using one way 
ANOVA followed by Dunnett’s test.
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nuclear translocation of NFAT1 (1–460)-GFP in the control group but such increase was not observed for cells 
treated with BTP2 and all the chosen drugs except leflunomide. For the latter, visually no significant increment in 
the NFAT1 (1–460)-GFP fluorescence within the nuclear region was apparent but surprisingly the corresponding 
nucleus to cytoplasmic ratio was found to be significantly high when compared to the basal (i.e. non-ionomycin 
treated group).
Evaluation of the effects of chosen drugs on the oligomerisation of STIM1 and Orai1. With 
a view to gaining some insight into the possible mechanism underlying the SOCE-inhibitor property of those 
5 drugs, we evaluated the effects of the drugs on the clustering of STIM1 and also of Orai1, using confocal 
microscopy with a HEK293 cell line with an inducible mCherry-STIM1-T2A-Orai1-eGFP19. When assessed 
Figure 2. Concentration-response curves demonstrating the dose-dependence of inhibitory effect of indicated 
drugs and BTP2 on the SOCE in RBL-1 cells triggered by Thapsigargin. SOCE was denoted by the peak Fura-2 
fluorescence ratio following Ca2+ add back during Ca2+ imaging experiment of RBL-1 cells loaded with Fura-
2AM. Each value (mean ± SEM) was derived from 3–5 individual experiments and a total of 60–100 cells.
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both qualitatively and quantitatively, we did not observe any significant change in the punctuate distribution of 
mCherry-STIM1 or Orai1-eGFP in presence and absence of any of the 5 drugs and BTP2, after cells were treated 
with 2 μM thapsigargin (Fig. 8, Supplementary Fig. 8). The results indicated that neither those drugs nor the 
known SOCE inhibitor, BTP2 affected STIM1 clustering or clustering of Orai1.
Discussion
To date, there are several small molecule inhibitors of SOCE available and these notably include 2-APB (ant its 
analogs such as DPB162-AE and DPB163-AE), BTP2 (also known as YM-58483 or Pyr2), Pyr6, Synta 66 and 
AnCoA43–6. Given the relative low potency and complex action of 2-APB on SOCE and on other ion chan-
nels5, we did not consider using 2-APB as bait. Since the other non-borinate SOCE inhibitors such as BTP2, 
Pyr6, Synta66 and AnCoA4 seem to have greater potency and selectivity, we used these agents as bait scaffolds 
(Supplementary Fig. 1) to scan conformer library made of drugs in clinical use. This led to identification of five 
drugs which suppressed SOCE significantly and dose-dependently in Ca2+ imaging using RBL-1 cells. The data 
was complemented by significant inhibition of ICRAC by these drugs in whole-cell recordings from these cells. The 
drugs also retained their ability to inhibit SOCE in SHSY-5Y cells, indicating that the observed effect was not 
cell type specific. We also found that potency of two drugs – leflunomide and teriflunomide for inhibiting SOCE 
significantly improves upon much longer pre-incubation and these two drugs also could significantly inhibit Ca2+ 
signals mediated by TRPC channels.
It is well established that in lymphocyte and relevant cell lines including RBL cells, SOCE-derived Ca2+ sig-
nals are critically required for the calmodulin-dependent activation of the phosphatase calcineurin. The latter 
then dephosphorylates and thus promotes the nuclear translocation of NFAT isoforms. This pathway can be 
impaired by inhibition of SOCE which can be due to either structural defect in the underlying proteins (for e.g. 
R91W mutation in CRAC channel pore) or presence of SOCE blockers. In fact, nuclear translocation assay with a 
fluorescently-tagged NFAT provides for a useful a phenotypic screen to identify SOCE modulators or evaluate the 
consequences of perturbing SOCE in intact cells2,3. Given the observed SOCE-inhibitory property of the chosen 
drugs, it was satisfying to see their complementary ability to retard nuclear translocation of NFAT1(1–460)-GFP 
in HeLa cells. The only very odd exception to this was leflunomide, which qualitatively indicated similar trend 
with other drugs but upon quantitative assessment, was proven to be not affecting the nucleus to cytoplasm ratio 
of NFAT1(1–460)-GFP, significantly. Whether this is a genuine property of leflunomide stemming possibly from 
any off target effects, needs to be investigated further.
Figure 3. Effects of selected compounds on CRAC current. (a) RBL-1 cells were pre-treated for ~20 min 
with BTP2 (10 μM), teriflunomide (20 μM) and tolvaptan (20 μM) whilst the control cells received DMSO. 
Representative current-voltage plots (mean ± S.E.M) from whole-cell recording of at least four different cells 
in each condition are shown. (b) Bar graphs (mean ± S.E.M) showing current densities at −100 mV holding 
potential under each condition. The statistical comparison among the values for all conditions was determined 
using one way ANOVA followed by Dunnett’s test.
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Figure 4. Effect of the chosen drugs on SOCE of RBL-1 cells following prolonged pre-treatment. Cells were 
treated with the indicated drugs at 1 μM dose for 24 hrs and then SOCE was triggered by thapsigargin and 
measured using standard protocol. (a) Sample traces of changes in Fura-2 fluorescence ratio representing 
Ca2+ signals following thapsigargin (2 μM) addition as well as Ca2+ add back under indicated conditions of 
pretreatment. (b) Histograms showing the peak SOCE levels triggered by Tg in control cells and cells pretreated 
with each drug at 1 μM dose for 24 hrs. Each value (mean ± SEM) was derived from 3–5 individual experiments 
and a total of 50–80 cells. The statistical comparison among the values for all conditions was determined using 
one way ANOVA followed by Dunnett’s test.
Figure 5. Effect of the chosen drugs given super-acutely on SOCE of RBL-1 cells. Indicated drugs at 50 μM dose 
were added to the extracellular solution ≤5 s (defined here as ‘super acute’ challenge) ahead of the Ca2+ addition 
during the Ca2+ imaging experiment using Fura-2. SOCE was triggered by thapsigargin and measured using 
standard protocol. (a) Sample traces of changes in Fura-2 fluorescence ratio representing Ca2+ signals following 
thapsigargin (2 μM) addition as well as Ca2+ add back under indicated conditions of drug pre-treatment. (b) 
Histograms showing the peak SOCE levels triggered by Tg in control cells and cells super-acutely exposed to 
each drug at 50 μM dose. Each value (mean ± SEM) was derived from 3–5 individual experiments and a total 
of 50–80 cells. The statistical comparison among the values for all conditions was determined using one way 
ANOVA followed by Dunnett’s test.
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In our typical experiments, cells were exposed to the drugs ~20 min prior to the Ca2+ add back during the 
Ca2+ imaging experiments. During this time, the drugs presumably had opportunities for, among many other 
things, acting against STIM1 oligomerisation and/or STIM1-Orai1 coupling that are critical for SOCE activation. 
We therefore sought to know whether the drugs could affect SOCE upon more acute challenge, which could at 
least indicate whether they could inhibit SOCE when Orai1 is already activated, presumably through interaction 
with aggregated STIM1 proteins. It turned out that leflunomide, teriflunomide and tolvaptan when added more 
acutely to the bath solution, retained their ability to inhibit SOCE. The known SOCE inhibitor - BTP2 as well as 
the other two drugs - roflumilast and lansoprazole were without any effect under such experimental condition. 
Previously, Ishikawa et al.20 reported BTP2 to be equally efficacious as SOCE inhibitor in Jurkat T cells regardless 
of instantaneous or prolonged treatment. However, in another study15, substantial SOCE inhibition by BTP2 was 
evident in Jurkat T cells only when the cells were pre-incubated with the agent for no less than 2 hrs. He et al.14, 
on the other hand, found BTP2 to block SOCE in HEK-293 cells, DT40 cells and A7r5 cells within 10 min of 
application. Thus variability in the degree of SOCE inhibition by BTP2 and related molecules seem to be plausible 
depending on cell types and/or duration of treatment. The reason for such variation remains still unclear.
The fact that leflunomide, teriflunomide and tolvaptan could inhibit SOCE substantially even at acute chal-
lenge is intriguing. This indicates that these drugs could act on Orai1 channels that are activated already presum-
ably via interaction with aggregated STIM1 proteins. In other possibilities, these drugs may act extracellularly 
or they may be readily cell-permeable if they act intracellularly. Although in acute challenge roflumilast and 
lansoprazole did not inhibit SOCE, it is difficult to be definitive about their lack of effect on STIM1 oligomeri-
sation and/or coupling of STIM1-Orai1. This is because the known SOCE inhibitor - BTP2 which had no effect 
on STIM1 puncta formation5, was also ineffective in our acute challenge experiment. We therefore sought out to 
assess directly the effects of the drugs on the clustering of STIM1 and also of Orai1, using confocal microscopy 
with a HEK293 cell line with an inducible mCherry-STIM1-T2A-Orai1-eGFP19. All the five drugs as well as the 
known SOCE inhibitor, BTP2 did not affect STIM1 clustering or clustering of Orai1. In previous studies, the 
pyrazole derivatives such as BTP2, Pyr6, GSK7975A, GSK5503A etc. did not affect STIM1 puncta formaton and 
thus their SOCE-inhibitory properties were attributed to their possible interaction with the Orai1 proteins5,21. 
However, AnCoA4 is so far only the SOCE inhibitor for which the target - Orai1 has been experimentally vali-
dated19. Given the significant similarities of the drugs with the baits used in our study (Supplementary Table 3, 
Supplementary Figs 3–6) and given the observation that they do not interfere with STIM1 puncta formation 
(Fig. 8, Supplementary Fig. 8) in particular, we hypothesize that these agents inhibit SOCE probably via interact-
ing with Orai1. This requires direct experimental validation in future.
It is interesting to note that leflunomide ranked the top (or nearly the top) in both ROCS and EON-based ranks 
of the hits obtained from screening with BTP2, Synta66 and Pyr6 as baits. Teriflunomide was also among the hits 
that ranked high in the lists, especially after re-ranking with EON (Supplementary Table 3). The EON-based elec-
trostatic surface representations indicate that the isoxazole ring of leflunomide and the acrylonitrile moiety of ter-
iflunomide share some electrostatic similarity with the o-fluoropyridyl group of Synta66 as well as the 4-methyl-1, 
Figure 6. Effect of the chosen drugs on OAG-evoked Ca2+ entry in RBL-1 cells. (a) Sample traces representing 
Ca2+ signals (indicated by Fura-2 fluorescence ratio) triggered by adding 100 μM of OAG to RBL-1 cells with or 
without pretreatment of the chosen drugs (shown in various coloured lines, each at 10 μM dose). OAG is well 
known to be a selective activator of the members of the TRPC family selectively. (b) Histograms showing the 
peak OAG-activated Ca2+ entry in control cells and cells treated with 10 μM of each drug. Each value (mean ± 
SEM) was derived from 3–5 individual experiments and a total of 30–80 cells. The statistical comparison among 
the values for all conditions was determined using one way ANOVA followed by Dunnett’s test.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 12881  | DOI:10.1038/s41598-017-13343-x
2,3-thiadiazole-5-carboxamide moiety of BTP2. Also the fluoro-phenyl group of leflunomide and terifluno-
mide share some similarity with the 3,5-bis (trifluoromethyl) pyrazole moiety of BTP2 (Supplementary Fig. 3). 
Leflunomide is a pro-drug and ~70% of the orally-administered leflunomide rapidly undergoes opening of the 
Figure 7. Effects of the chosen drugs and BTP2 on nuclear transolcation of NFAT. (a) Representative confocal 
images of HeLa cells showing subcellular localisation of NFAT (1–460)-GFP following application of ionomycin 
(1 μM for 40 min) preceded by pretreatment with the chosen drugs (20 μM) and BTP2 (10 μM) for 30 min. The 
basal and control groups received only DMSO pretreatment and no ionomycin was added to the basal group 
subsequently. (b) Bar graphs showing the nucleus to cytoplasm ratio (mean ± S.E.M.; n = 3) for the NFAT 
(1–460)-GFP under various conditions.
www.nature.com/scientificreports/
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isoxazole ring to produce the active malononitrilamide metabolite - teriflunomide22 (Supplementary Fig. 3). Both 
these agents have been clinically used as orally-active, disease-modifying immunosuppressive drugs for treating 
inflammatory diseases, often of autoimmune type. Leflunomide (Arava®) was approved and licensed in 1998 for 
Figure 8. Effects of chosen drugs on clustering of STIM-1 and Orai-1 protein. (a) Representative fluorescent 
images of HEK293 cells coexpressing mCherry-STIM1 (red) and Orai1-eGFP (green) showing translocation 
and colocalization of both proteins in characteristic puncta after treatment with thapsigargin (Tg) (2 μM for 
5 min). The scale bar is shown. GFP, green fluorescent protein. Quantification of mCherry-Stim1 (b) and GFP-
Orai1 (c) puncta formation in response to Tg treatment and the effect of pre-treatment with drugs. The number 
of puncta formed in cells belonging to the control (no Tg/drug treatment) and the Tg-treated groups were 
determined using ImageJ software and were expressed as mean/μm2 of area ± SEM. Each bar represents data 
from 15–18 cells from 3 different experiments. The statistical comparison among the values for all conditions 
was determined using one way ANOVA followed by Dunnett’s test.
www.nature.com/scientificreports/
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the treatment of rheumatoid arthritis and psoriatic arthritis, whereas teriflunomide (Aubagio®) was synthesized 
later, approved and licensed in 2012 for the treatment of multiple sclerosis. Hitherto the only mechanism known 
for their immunosuppressive activity involves teriflunomide-mediated non-competitive, reversible inhibition of 
the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) - an enzyme expressed at high levels in pro-
liferating lymphocytes. This results in blockade of de novo pyrimidine biosynthesis and therefore, reduced pro-
liferation of activated lymphocytes22. However, there are some other cellular effects due to teriflunomide intake 
which cannot be explained by DHODH inhibition solely. These include impairment of cytokine production and 
expression of cell-surface molecules as well as cellular migration23. Thus it is fair to state that teriflunomide has 
immunological effects outside of its ability to inhibit pyrimidine synthesis in rapidly proliferating lymphocytes. 
So far it is known that higher doses of leflunomide and, consequently, of teriflunomide can inhibit few other tar-
gets including protein tyrosine kinases, cyclooxygenase-2, PDK1, NFκB, integrins etc22.
The average steady-state maximum plasma concentrations (Cmax) of teriflunomide achieved with doses used 
in clinical trials are 72 μM (7 mg) and 168 μM (14 mg)24. Thus based on our findings, teriflunomide and its prod-
rug leflunomide at clinically-relevant doses should have substantial inhibitory effect on SOCE. We propose that 
such effect should serve as an additional mechanism that significantly contributes to the observed biological 
effects and therapeutic benefits of these immunosuppressive drugs. Inhibition of SOCE can easily be correlated 
with decreased production of chemokines, decreased migration and proliferation lymphocytes, as observed for 
teriflunomide and/or leflunomide. That latter is indicated for rheumatoid arthritis and few recent studies have 
shown that SOCE inhibition can be an attractive strategy in treating such autoimmune diseases25–27.
Tolvaptan and conivaptan are orally and intravenously effective nonpeptide antagonists for the arginine vas-
opressin (AVP) receptor subtypes. These drugs are categorized as aquaretics i.e. they promote excretion of water 
without the loss of electrolytes and as such have been useful in treating hyponatremia28,29. In our ligand-based 
screening using BTP2, Synta66 and Pyr6, tolvaptan was within the top 20 of the hits ranked on the basis of ROCS 
and EON-based analysis. Conivaptan was within top 100 in ROCS and EON-based analysis of hits from Pyr6 and 
Synta66-based screening (Supplementary Table 3). Visually there were some similarities between the vaptans and 
the three individual baits (Supplementary Fig. 4). When screened in Ca2+ imaging at 10 μM dose (Fig. 1c), tol-
vaptan could still inhibit SOCE significantly whilst conivaptan was active only at 100 μM dose (Fig. 1b). Tolvaptan 
at therapeutic doses is however unlikely to affect SOCE as the Cmax following a single 60 mg oral dose of tolvaptan 
to human subjects with normal kidney function was sub-micromolar28,30.
Omeprazole and lansoprazole (Supplementary Fig. 5) are gastric proton pump inhibitors and as such are 
widely used in treating peptic ulcer as well as few other gastroesophageal diseases including Helicobacter pylori 
infection31. Both these agents were within top 10 hits based on EON-ranking of hits derived from AnCoA4-based 
screening. Besides, omeprazole in particular also was within the top 50 hits based on EON-ranking of hits derived 
from screening with the other three baits (Supplementary Table 3). Qualitatively, these two drugs seem to share 
some similarities in surface electrostatics with the baits (Supplementary Fig. 5). Although omeprazole looked 
better in computational analysis (Supplementary Table 3), lansoprazole was more potent in inhibiting SOCE 
(Fig. 1c). However, the Cmax of lansoprazole and omeprazole at clinically relevant oral doses (15–30 mg) is likely 
to be ≤ 3.5 μM31 and thus little effect on SOCE is predicted for this drug during clinical uses.
Roflumilast is an orally-active, selective inhibitor phosphodiesterase isoform 4 (PDE4) and as such it is 
approved for treating inflammatory conditions of the lungs such as chronic obstructive pulmonary disease 
(COPD). Selective inhibition of PDE4 by roflumilast has largely been attributed to its active metabolite – roflu-
milast N oxide. We included roflumilast in our final list of drugs for wet testing mainly because of the fact that 
this drug ranked second in both BTP2 as well as Pyr6-based screening using ROCS. Such high placement in the 
ranking seems to be due to significant similarity in 3D shape rather than in surface electrostatics (Supplementary 
Fig. 6). Besides, it was also among the top 55 hits in ROCS as well as EON-based ranking using AnCoA4 as the 
bait (Supplementary Table 3). At therapeutic doses (usually 500 μg once a day), the Cmax of roflumilast N-oxide 
remains within low nanomolar range32, and therefore little effect on SOCE is anticipated.
Conclusions
In summary, we have used 3D shape and electrostatics-based in silico screening to identify drugs that can inhibit 
SOCE dose-dependently, with no such prior records. It is noteworthy that two hits namely leflunomide and ter-
iflunomide, could suppress SOCE significantly at therapeutically-achievable concentrations and this can poten-
tially contribute to their observed immunosuppressive and other cellular effects. For the other three drugs namely 
lansoprazole, tolvaptan and roflumilast, the concentrations required to inhibit SOCE significantly are higher than 
cognate therapeutically-achievable maximum concentrations. They however, were more selective towards SOCE, 
unlike leflunomide and teriflunomide and thus can potentially serve as leads for future development of specific 
SOCE inhibitors.
Methods
Virtual screening, hit ranking and selection. We used the latest version of the eDrugs3D database 
(updated in July 2016) that contains 1822 molecular structures comprising of 3D representations along with iso-
mers of total 1557 FDA-approved drugs10. For each drug, up to 100 conformers were generated using OMEGA33 
(version 2.5.1.4, OpenEye Scientific Software, Santa Fe, NM, USA). The query molecules (SOCE inhibitors) such 
as BTP2, Synta663, Pyr634 and AnCoA419 were drawn and energy-minimized with the Merck Molecular Force 
Field 94 using the ChemBioOffice Ultra 11.0 (CambridgeSoft Corporation, Cambridge, MA, USA). The ener-
gy-minimized structures of the query molecules were then used for generating the 3D queries (Supplementary 
Fig. 1). Each of the latter was then utilized to scan the above mentioned conformer library generated from 
eDrugs3D by using Rapid Overlay of Chemical Screens (ROCS)35 (version 3.2.1.4, OpenEye Scientific Software, 
Santa Fe, NM) and all resulting hits were ranked with Tanimoto Combo (TC) score that represents a numerical 
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sum of the shape Tanimoto (maximum value = 1) and scaled colour Tanimoto score (maximum value = 1). We 
did not impose any cut off value for the TC score but limited the size of the screening output to 500 molecules. 
The ROCS output was then used as an input to EON (version 2.2.0.5, OpenEye Scientific Software, Santa Fe, NM) 
for re-ranking the aligned molecules on the basis of their electrostatic similarity with the cognate query ligand. 
For this, the EON Tanimoto combo (ET combo) score was used which is the sum of the EON Poisson-Boltzmann 
and EON Shape Tanimoto scores. Default parameters were used throughout. VIDA (version 4.3.0.4, OpenEye 
Scientific Software, Santa Fe, NM) was used to visualize and analyze the outputs from screening done with ROCS 
and EON. VIDA and MacPyMol (version 1.7.2.1) were used for molecular representations.
For each query molecule, we visually inspected each hit molecule using VIDA and shortlisted 11 can-
didates on the basis of several aspects including their similarity in electrostatic isopotential contour surfaces 
(EON-generated) with the cognate bait, their TC score and ET_pb score, their rank and frequency of appearing 
within the top 100 hits in ROCS as well as EON based screening, previous reported activity on calcium signalling 
and availability. The chosen molecules were purchased for bioassay. The drugs were dissolved in Ca2+-free Hank’s 
balanced salt solution (HBSS) or 10% DMSO.
All computational works were done in a Dell™ Precision Tower 7810 workstation (Intel® Xeon® Processor 
E5-1650 V3, 6 core, 3.5 GHz, 32GB RAM) run with 64 bit Windows 7 Professional as the operating system.
Materials. Leflunomide, teriflunomide, tolvaptan and BTP2 were purchased from Tocris Bioscience (Bristol, 
UK). Omeprazole, lansoprazole, rufinamide, prazosin hydrochloride, terazosin hydrochloride, flutamide, roflu-
milast and propidium iodide were purchased from Sigma-Aldrich (Dorset, UK). Conivaptan hydrochloride 
was purchased from Selleckchem (distributed by Stratech, Suffolk, UK) and OAG was purchased from Cayman 
Chemicals (distributed by Cambridge Bioscience, Cambridge, UK). All molecules were of ≥98% purity certified 
by the vendors.
Cell culture and media. RBL-1 cells were kindly provided by Professor Anant Parekh (Department of 
Physiology, Anatomy and Genetics, University of Oxford) and grown in RPMI 1640 medium supplemented with 
10% fetal calf serum and maintained at 37 °C in 5% CO2 as mentioned previously36. SH-SY5Y cells were kindly 
provided by Professor Robin Irvine (Department of Pharmacology, University of Cambridge) and cultured in 
high glucose DMEM medium with the F-12 nutrients mixture, supplemented with 10% (v/v) fetal bovine serum, 
2 mM L-glutamine and 1% (v/v) antibiotic/antimycotic mixture in humidified atmosphere with 5% CO2 and 
95% air at 37 °C. A HEK293 cell line with an inducible mCherry-STIM1-T2A-Orai1-eGFP was kindly provided 
by Dr. Chan Young Park (School of Life Sciences, UNIST, South Korea) and was grown and maintained as per 
published report19. Cells were kept at 75 cm2 flask and passaged at least once in a week after reaching ~90% con-
fluence. SH-SY5Y cells and RBL-1 Cells were not used beyond passage 25 and 16 respectively. In preparation for 
the passage of the cells, DMEM and trypsin media were pre-warmed at 37 °C. Cell medium from the flask was 
aspirated and cells were detached from the flask through addition of 2/3 ml of trypsin. After 2/3 min, the flasks 
were gently shaken to allow complete detachment of adhered cells and then trypsin was neutralized by adding 
8–10 ml of DMEM. The cell suspension was then gently pipetted few times before it was centrifuged at 800 rpm 
for 5 minutes after which the supernatant was discarded and the cell pellet was re-suspended in DMEM (10 ml). 
The resultant cell suspension was used for seeding of cells into flasks and onto glass bottom dishes (10 mm) as 
required for Ca2+ signal recording.
HeLa cells stably expressing the NFAT1(1–460)-GFP fusion protein were a kind gift from Professor Patrick 
Hogan (La Jolla Instiute for Allergy and Immunology, CA, USA) and grown as per published protocol18.
Measurement of intercellular Ca2+. Intracellular Ca2+ levels were measured by ratiometric imaging 
using fura-2 largely in accordance with previously published protocol12. Ratio fluorescence images were captured 
using a QIClick™ digital CCD camera (QImaging, BC, Canada) mounted on a Nikon Eclipse Ti-S Microscope. 
Consecutive excitation was provided by a Dual OptoLED Power Supply (Cairn), alternating between both 355 nm 
(F355) and 380 nm (F380) wavelength LEDs. Emission fluorescence was collected at 510 nm (470 nm–550 nm). 
12-bit images were acquired in every 5 seconds with MetaFluor® (Molecular Devices, USA) Fluorescence Ratio 
Imaging Software. The fluorescence at each time-point was extracted for both 355 nm and 380 nm wavelengths, 
corrected for autofluorescence and the 355 nm/380 nm ratios (F355/F380) were then calculated to represent intra-
cellular Ca2+ levels. All Ca2+ imaging experiments were done in room temperature.
Confocal Microscopy. Cells were plated onto sterilized cover slips coated with poly-D-lysine and main-
tained in complete DMEM. STIM1-mCherry and Orai1-GFP protein were induced through tetracycline 
(2–5 μM) treatment as per published protocol19, 12–16 hours before the experiment. Cells were washed with 
HBSS and incubated for 10–15 minute with the respective drug followed by 2 μM of TG treatment for 5 min. Cells 
were fixed with ice cold methanol (100%).
Confocal images were acquired using a Leica SP5 microscope equipped with a Plan Apochromat 63x/NA1.4 
oil immersion objective. The excitation wavelengths (ex) and emission filters (em) were as follows: DAPI, ex 
364 nm/em 385–470 nm; Orai1-GFP or NFAT1(1–460)-GFP, ex 488 nm/em 500–515 nm; STIM1-mCherry, 
ex 543 nm/em 610 nm. Acquired images were processed using the ImageJ (National Institutes of Health). For 
quantification of STIM1–mCherry and Orai1-GFP puncta formation, the puncta were selected as spots of high 
fluorescence intensity ranging from approx. 0.5 to 1.0 μm in diameter and their number was determined as per 
previously published method37.
For the quantitative assessment of the ionomycin (1 μM for 40 min)-induced nuclear translocation of 
NFAT1(1–460)-GFP in HeLa cells with or without drug/BTP2 pretreatment, the method described by Kar et al.17 
was followd. All images were prepared for publication using Adobe Photoshop.
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Evaluation of cytotoxicity. Cell death was assessed by propidium iodide staining as per the method previ-
ously published by Lecoeur13. Briefly, RBL-1 cells were first treated with drugs (the maximum concentration used 
in functional assay i.e. 300 µM), BTP2 (30 µM) or vehicle (2 µM DMSO). Afterwards, cells were incubated with 
10 µg/ml propidium iodide for 20 min at 37 °C. Cells were then washed with PBS and fixed for 15 min with 100% 
ice cold methanol in −20 °C. Cells within each treatment group were later imaged using confocal microscopy 
with the 20x objective.
Electrophysiology. CRAC currents (ICRAC) were recorded from RBL-1 cells at the room temperature (22–
25 °C) in the tight-seal, whole-cell configuration as previously described38. Patch pipettes were pulled from boro-
silicate glass capillaries (World Precision Instruments, Hitchin, UK) and fire polished. Pipettes had resistances of 
2.5–4 MΩ when filled with standard internal solution containing (in mM): cesium glutamate 145, NaCl 8, MgCl2 
1, MgATP 2, EGTA 10, HEPES 10, pH adjusted to 7.2 with CsOH. IP3 (30 μM) was also included in the pipette 
solution. Extracellular solution contained (in mM): NaCl 145, KCl 2.8, CaCl2 10, MgCl2 2, CsCl 10, glucose 10, 
HEPES 10, pH adjusted to 7.4 with NaOH. All voltages were corrected for a liquid junction potential of +10 mV 
between external and internal solutions. ICRAC was measured using voltage ramps (−100 to +100 mV in 50 ms) 
applied every 2 s. Axopatch 200 B and Digidata 1440 A (Molecular Devices) with pCLAMP 10 software were 
used for data acquisition and analysis. Data were digitized at 10 kHz and filtered at 1 kHz. Cells were held at 0 mV 
between pulses. Capacitative currents were cancelled before each voltage ramp. Uncompensated series resistance 
was in the range of 5–14 MΩ. All leak currents were subtracted by averaging the first 2–3 ramp currents obtained 
just after the break in and then subtracting this from all subsequent currents. Amplitude of the current was nor-
malized to cell size and expressed in pA/pF. Cells were pre-treated with BTP2 (10 μM)/ drugs (20 μM) for ~20 min 
prior to recording.
Statistical analysis. Results were expressed as means ± SEM for n independent experiments, with each 
experiment performed minimally in triplicate. The latter in this study involved Ca2+ imaging of drug-treated cells 
in three different days (at least 3 petri-dish of cells per drug per day) done with paired control group (3 petri-dish 
of cells per day). One way ANOVA followed by a post hoc (Dunnett) test was to identify significant differences, 
unless specified otherwise. Statistical significance was set at P < 0.01 and all statistical analyses were done using 
GraphPad Prism 5 (GraphPad software Inc., CA, USA).
Data availability statement. Most of the data generated or analyzed during this study are included in 
this article (and its Supplementary information files). Detailed lists of hits obtained with four different baits are 
available from the corresponding author on reasonable request.
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